complicated by bleeding once in addition to multiple presentations to ER and outpatient clinic with recurrent DVT. During one of these episodes, the patient presented with altered visual acuity, and was diagnosed to have left eye retinal vein thrombosis which further deteriorated to complete visual loss. The patient has no family history of BD, other thromboembolic or vasculitic disorders. Unexpectedly, he presented again with DVT despite being on VKA and low molecular weight heparin (LMWH) most likely due to poor compliance, then rivaroxiban was discussed as analternativetreatment. The patient informed aboutthe uncertain use of this medication, side effecst and the fact that there is no evidence of its effectiveness in treating or preventing VT in his disease. Patient commenced on rivaroxaban with satisfying outcome for four years of regular follow-up with no complications or features of vascular thrombosis. The compliance improved as patient felt more comfortable without having repeated INR monitoring. The patient has had an uneventful clinical course after startingrivaroxaban. Discussion: This is the first known case of BD in Saudi Arabia where the frequency of venous thromboembolic events were successfully managed with rivaroxaban over a course of over four years of outpatient follow-up. BD has a high prevalence in the Mediterranean, and considerable prevalence in others. Vascular BD is unique in affecting both arterial and venous systems and is a major cause of morbidity and mortality, despite there being no clear guidelines for the treatment and secondary prevention of VBD. Immunosuppressive agents have demonstrated significant reduction of venous thromboembolic events in BD; however, in clinical practice we often encounter patients with BD who have recurrent VT while on immunosuppressant medications, and oral VKA (warfarin) with the commonest reason cause being sub-therapeutic drug levels due to poor compliance or intolerance. Rivaroxaban has a fixed dose and doesn't require blood monitoring. Moreover, it has limited drugs interactions. It has been proven to be effective, safe and has significant impact in decreasing the recurrence of VT with lower risk of gastrointestinal bleeding and subsequent complications comparing to VKA in situations other than BD. Patients with DVT treated with rivaroxiban have a lower rate of hospitalisation and outpatient visits without increasing the risk of readmission. Rivaroxaban has shown a great result in treatment and secondary prevention in this patient, so this might open a new line of treatment and secondaryprevention of VBD if proven infurtherclinical trials. Key Learning Points: BD is rare but has serious complications, especially vascular issues, if not detected and treated carefully. There are no new guidelines in the treatment of BD. Although immunosuppressive agents proved reduction in vascular complications in BD, we still face patients with venous thrombosis despite being on immunosppressant medications. Rivaroxaban might be a new line in treatment and secondary prevention of vascular BD ifprovenin further clinical trials.
Rheumatology, Great Western Hospital, Swindon, UNITED KINGDOM Introduction: We present a case of a 68 year old female who was admitted with stridor, and subsequently diagnosed with localised subglottic amyloid. The case highlights the importance of keeping an open mind to a wide differentialto ensure that rare causes are not missed. Case description: A 68 year old female patient presented with stridor requiring an emergency tracheostomy. She had a preceding history of two years of a hoarse voice and had recently had a microlaryngoscopy and biopsy of a granuloma on the left vocal cord. Further examinations of the subglottic area revealed oedema with friable areas, and the subglottic biopsy showed amyloid deposition. She was systemically well, with no symptoms elsewhere. She was investigated for causes of secondary amyloid but none found. Her inflammatory markers were normal, ANCA, ANA and anti-CCP were negative with normal serum ACE and complement levels. Serum electrophoresis and bone marrow biopsy were both normal. She was started on a reducing regimen of prednisolone with clinical improvement and successfully extubated. After discharge, she went on to have a SAP scan which showed the amyloid to be localised to the subglottic area, and a subsequent CT-PET showed the biopsy proven amyloid area to be markedly FDG avid with disease extending inferiorly along the trachea Over the next month, she developed increasing shortness of breath on exertion and stridor, requiring up to 40mg prednisolone, and has been referred for consideration of surgical intervention. Discussion: Localised amyloid is a rare disease. In a study at the National Amyloid Centre between 1980 and 2011, 12% of all newly diagnosed patients with amyloid had localised disease with a median age was 59.5 years. 15% of these patients had amyloid localised to the larynx or tonsils. Primary laryngeal amyloidis seen moreoften within the laryngeal ventricle or vocal cords with subglottic involvement being less common. It presents with dysphonia and stridor, and as in our patient, may result in airway compromise. Our patient was initially referred to rheumatology with a possible diagnosis of subglottic granulomatosis with polyangiitis (GPA), which may also be localised to the subglottic area and present with similar symptoms. ANCA may also be negative in patients with limited GPA. Consideration of localised amyloid as an alternative is important and CongoRedstaining onbiopsy will confirm the diagnosis. The prognosis of localised amyloid is generally good, with an estimated five-year overall survival of 90Á6% in the National Amyloid Centre study. Although the literature suggests that steroids are not of benefit in localised laryngeal amyloid, our patient appeared to gain clinical benefit from them. The mainstay of treatment is carbon dioxide laser excision, which may need to be repeated. Key Learning Points: Subglottic stenosis may be an airway threatening problem. Localised amyloid should be included in the differential diagnosis for these patients and Congo Red staining performed on biopsy specimens. All patients with localised amyloid should be carefully evaluated for systemic amyloid,and causes of secondaryamyloid. Medicine, Changi General Hospital, Singapore, SINGAPORE Introduction: Medication, herbal and dietary supplement induced lupus and liver injuries have been well documented in the literature. We report two cases of skyfruit seed induced autoimmune phenomena and hepatic injury. Swietenia macrophylla seeds, also known as skyfruits or mahogany seeds in Southeast Asia have been used as a remedy for diabetes,hyperlipidemiaandshown tohaveantibioticproperties byitseffect on the innate immune system. Due to its perceived benefits, it is being used as part of traditional medication in Southeast Asia for various ailments. Case description: A 62 year-old Indian male with a history of diabetes mellitus, hypertension, hyperlipidaemia, coronary artery disease and non-alcoholic fatty liver disease presented to the gastroenterology clinic for transaminitis. He had been on stable doses of medications for the above including atorvastatin 10mg ON for the last one year. He presented with polyarthralgia with tenosynovitis and severe restriction of motion of his right shoulder, left wrist and dorsum of right hand at onset with minimal response to a short course of prednisolone. His symptoms improved but were still present until review in the rheumatology clinic six weeks later. Of note he had taken skyfruit seeds six weeks ago. Systemic review was negative for rashes, oral ulcers, sicca symptoms, Raynaud's, hematuria, frothy urine or abdominal pain. He reported a significant unintentional weight loss of 14kg in the preceding 12 months. There was no family history of autoimmune conditions. Physical examination showed synovitis of the right metacarpophalangeal and proximal interphalangeal joints. Full blood count, renal function and thyroid function tests were normal. His liver function test showed transaminitis with alanine transaminase (ALT) of 699 U/L , aspartate aminotransferase (AST) of 645 U/L and gamma-glutamyl transferase (GGT) of 125 U/L. C-reactive protein (CRP) was 75.7 mg/L. Anti-nuclear antibody (ANA) screen was positive; anti-ENA (extractable nuclear antigen) profile and rheumatoid factor were negative. Anti-mitochondrial M2, anti-liver cytosol 1, anti-liver kidney microsomal and anti-soluble liver antibodies were negative. Hepatitis B surface antigen and antibodies against hepatitis A, C and E were nonreactive. He realized that the onset of symptoms -arthritis, weight loss and transminitis correlated with his intake of skyfruit seeds and stopped consuming them. The inflammatory arthritis had completely resolved and CRP and liver enzymes had markedly improved six weeks later. Within a year, his liver function tests had normalised and he had no recurrence of his arthritis. A 59 year-old Chinese female, previously well, presented with right upper quadrant discomfort for two weeks. Liver function tests were deranged with a total bilirubin 1.51 umol/L, ALT 859 U/L, AST 491 U/L and GGT 98 U/L. Hepatitis B, hepatitis C and human immunodeficiency virus (HIV) antibodies were non-reactive. A CT (Computed tomography scan) of the abdomen and pelvis showed fatty liver, and mesenteric panniculitis with prominent mesenteric nodules. She had noted a 6kg weight loss over six weeks and loss of appetite. Oesophagogastroduodenoscopy and colonoscopy showed chronic atrophic gastritis without dysplasia or malignancy. She had started taking five sky fruit seeds daily for duration of one month prior to presentation. Systemic review was negative for features of connective tissue diseases.Her physical examinationwas normal except for dry skin over hands and feet related to frequent ablutions. Her i28 September 2018 CASE REPORTS
